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Leukemic stem cells (LSCs) are an emerging target of curative anti-leukemia therapy. In acute lymphoblastic
leukemia (ALL), LSCs frequently express CD34 and often lack CD38. However, little is known about markers and
targets expressed in ALL LSCs. We have examined marker- and target expression profiles in CD34+/CD38− LSCs
in patients with Ph+ ALL (n = 22) and Ph− ALL (n = 27) by multi-color flow cytometry and qPCR. ALL LSCs
expressed CD19 (B4), CD44 (Pgp-1), CD123 (IL-3RA), and CD184 (CXCR4) in all patients tested. Moreover, in
various subgroups of patients, LSCs also displayed CD20 (MS4A1) (10/41 = 24%), CD22 (12/20 = 60%), CD33E-mail: peter.valent@meduniwien.ac.at
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Neoplasia Vol. 20, No. xx, 2018 Blatt et al. 633(Siglec-3) (20/48 = 42%), CD52 (CAMPATH-1) (17/40 = 43%), IL-1RAP (13/29 = 45%), and/or CD135 (FLT3) (4/
20 = 20%). CD25 (IL-2RA) and CD26 (DPPIV) were expressed on LSCs in Ph+ ALL exhibiting BCR/ABL1p210,
whereas in Ph+ ALL with BCR/ABL1p190, LSCs variably expressed CD25 but did not express CD26. In Ph
− ALL,
CD34+/CD38− LSCs expressed IL-1RAP in 6/18 patients (33%), but did not express CD25 or CD26. Normal stem
cells stained negative for CD25, CD26 and IL-1RAP, and expressed only low amounts of CD52. In
xenotransplantation experiments, CD34+/CD38− and CD34+/CD38+ cells engrafted NSG mice after 12–20
weeks, and targeting with antibodies against CD33 and CD52 resulted in reduced engraftment. Together, LSCs in
Ph+ and Ph− ALL display unique marker- and target expression profiles. In Ph+ ALL with BCR/ABL1p210, the LSC-
phenotype closely resembles the marker-profile of CD34+/CD38− LSCs in chronic myeloid leukemia, confirming
the close biologic relationship of these neoplasms. Targeting of LSCs with specific antibodies or related
immunotherapies may facilitate LSC eradication in ALL.
Neoplasia (2018) 20, 632–12Introduction
Acute lymphoblastic leukemia (ALL) is a life-threatening malignancy
defined by leukemic expansion and accumulation of lymphoid blast
cells in hematopoietic tissues, including the bone marrow (BM),
spleen, and lymph nodes [1,2]. The clinical course and prognosis vary
among patients, depending on age, comorbidities, the variant of ALL,
and cytogenetic and molecular features. In approximately one third of
all adult patients, ALL cells display the Philadelphia chromosome
(Ph) and the associated BCR/ABL1 oncogene [1–5]. In most cases,
leukemic cells display the p190-form of BCR/ABL1, whereas in a
smaller group of patients, BCR/ABL1p210 is found.
Before BCR/ABL1 blockers had been introduced in clinical
practice, patients with Ph+ ALL had a quite unfavorable prognosis
[3–5]. However, since the advent of imatinib and other more effective
BCR/ABL1-targeting tyrosine kinase inhibitors (TKIs), the prognosis
of Ph+ ALL has improved substantially [3,6–14]. Nevertheless, not all
patients respond to chemotherapy or/and to targeted drugs
[8–12 ,14] . Depend ing on age , co -morb id i t i e s and
donor-availability, stem cell transplantation (SCT) is recommended
for high-risk patients [15–20]. The overall treatment plan may
include chemotherapy with subsequent SCT as well as BCR/
ABL1-targeting drugs [16,18,19]. However, despite SCT and other
treatment options, not all patients with ALL can be cured. Therefore,
current research is attempting to identify new drug-targets and novel
treatment approaches, including immunotherapies and other targeted
therapies, with the hope to improve treatment outcome and
prognosis.
An emerging new target of therapy in clinical hematology is the
leukemic stem cell (LSC). The concept of LSCs has been established
with the intention to explain cellular hierarchies in leukemic clones,
and to improve drug therapy through the elimination of
disease-initiating cells [21–27]. The LSC-hypothesis is based on the
assumption that leukemias are organized hierarchically, with more
mature cells programmed to undergo apoptosis after a limited
number of cell divisions, and LSCs which have self-renewal and thus
unlimited disease-propagating ability [21,23–25]. In Ph+ chronic
myeloid leukemia (CML), LSCs are considered to reside within a
CD34+/CD38− fraction of the clone [22,23,28,29]. In ALL, the
phenotype of LSCs is less well defined. In adult patients with Ph+
ALL, NOD/SCID-repopulating LSCs supposedly reside within aCD34+/CD38− compartment [30–32]. However, in other (child-
hood) variants of ALL, NOD/SCID-repopulating LSCs may also be
detectable in other CD34+ sub-fractions or even in CD34−
populations [31–33]. Overall, little is known about markers and
target expression profiles in ALL LSCs.
The aim of the current study was to establish the phenotype and
target expression profile of LSCs in Ph+ and Ph− ALL in adults. Our
data show that depending on the type of ALL, LSCs exhibit unique
phenotypes and variable combinations of aberrantly expressed surface
targets which may assist in LSC purification and the development of
LSC-eradicating treatment strategies.
Material and Methods
Patients and Cell Lines
Peripheral blood (PB) and/or BM samples were collected in 49
patients with ALL and 10 with Ph+ CML. The patients´
characteristics are shown in Supplementary Table S1. All patients
gave written informed consent before blood or BM was obtained. The
study was approved by the ethics committee of the Medical University
of Vienna. The following cell lines were used: the Ph+ cell lines Z-119
(RRID:CVCL_IU88), BV-173 (RRID:CVCL_0181), TOM-1 (RRID:
CVCL_1895) and NALM-1 (RRID: CVCL_0091), the Ph− cell lines
RAJI (RRID: CVCL_0511), RAMOS (RRID: CVCL_0597), REH
(RRID: CVCL_1650) and BL-41 (RRID: CVCL_1087), the CML cell
line CML T1 (RRID: CVCL_1126), and the myeloid cell line M-07e
(RRID:CVCL_2106) expressing or lacking BCR/ABL1. A detailed
description is provided in the Supplement.
Monoclonal Antibodies (mAb) and Other Reagents
A detailed description of reagents used in this study is provided in
the Supplement. A list of mAb employed is shown in Supplementary
Table S2.
Flow Cytometry and Cell Sorting
Flow cytometry was performed on heparinized BM or PB cells or
MNCs to characterize the phenotype of CD34+/CD38− and
CD34+/CD38+ cells as described [29,34,35]. The gating-strategy is
shown in Supplementary Figure S1 and the antibody-combinations
applied in Supplementary Table S3. In selected patients with Ph+
ALL (n = 6), Ph− ALL (n = 6), and CML (n = 3), CD34+/CD38− and
Table 1. Expression of Lineage-related Markers, Stem Cell Markers, and Niche-related Antigens on ALL LSCs, CML LSCs, and Normal CD34+/CD38− Bone Marrow (BM) Stem Cells
Expression of Marker/Antigen on CD34+/CD38− Cells in
BCR/ABL1p210 BCR/ABL1p190
CD Marker/Antigen T ALL Ph− ALL Ph+ ALL Ph+ ALL CML Normal BM
CD10 CALLA n.t. − + + n.t. −
CD19 B4 − + + + +/− −
CD22 Siglec-2 n.t. +/− + + n.t. −
CD25 IL-2RA − − + +/− + −
CD26 DPPIV − − + − + −
CD43 Leukosialin n.t. + + + + +
CD44 Pgp-1 n.t. + + + + +
CD51 VNRA n.t. − − − −/+ −
CD61 VNRB n.t. − − − − −
CD90 Thy-1 n.t. − +/− +/− +/− +/−
CD96 Tactile − − − − − −
CD117 SCFR/KIT + −/+ − − + +
CD133 Prominin-1 n.t. +/− −/+ − + +
CD150 SLAMF1 − − − − − −
CD167a DDR-1 n.t. − − − − −
CD184 CXCR4 n.t. + + + +/− +/−
CD243 MDR-1 − − − − − −
CD371 CLL-1 n.t. − − − − −
n.c. IL-1RAP +/− +/− + +/− +/− −
n.c. ROBO-4 n.t. − − − +/− n.t.
n.c. HLA-DR n.t. + + + + +/−
Expression of surface markers on CD34+/CD38− BM cells was determined by multi-color flow cytometry as described.30,35,36 Technical details are provided in the Supplement.
Abbreviations: ALL, acute lymphoblastic leukemia; LSCs, leukemic stem cells; CML, chronic myeloid leukemia; BM, bone marrow; CD, cluster of differentiation; n.c., not yet clustered; n.t., not tested. Score of reactivity: +,
LSCs positive (median fluorescence intensity (MFI) N3) in N80% of patients; +/−, LSCs positive in 30–80%; −/+, LSCs positive in 10–29%; −, LSCs positive in b10% of patients. Antibody staining results obtained in each
individual ALL patient are shown in Supplemental Table S5.
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sorting on a FACSAria (BDBiosciences, San José, CA,USA) as described
[29,34,35].
Quantitative PCR (qPCR)
qPCR was performed as reported [35,36] using primers shown in
Supplementary Table S4 and RNA from cell lines, unfractionated
MNCs and sorted CD34+/CD38− and CD34+/CD38+ cells. mRNA
levels were quantified on a QuantStudio-3 Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA) using iTaq
SYBR Green Supermix with ROX from Bio-Rad (Hercules, CA,
USA). ABL1 served as reference gene.
Evaluation of In Vitro Effects of Targeted Drugs on ALL Cells
Primary ALL cells, CD34+ sub-fractions (CD34+/CD38− and
CD34+/CD38+) and cell lines were incubated in control medium or
various concentrations of gemtuzumab-ozogamicin (GO) (48 hours),
rituximab (1 hour), or alemtuzumab (1 hour) at 37 °C. After
incubation, the percentage of viable cells was determined by
AnnexinV and/or PI staining essentially as described [37]. In a
separate set of experiments, proliferation of drug-exposed cells was
examined by measuring 3H-thymidine uptake. Drug combination
effects were determined as reported [29,35,36]. A detailed description
of drug incubation experiments is provided in the Supplement.
Xenotransplantation of ALL Cells
NOD.Cg-Prkdc scid Il2rg tm1Wjl/SzJ mice (NSG; RRID:
IMSR_ARC:NSG) were used to study in vivo engraftment of
untreated or drug-pre-incubated ALL cells (total MNCs depleted of
CD3+ T cells or sorted CD34-subfractions) or CD52+ BL-41 cells.
Twenty four hours prior to injection, mice were irradiated in flat
(sterile) irradiation-cages (2.4 Gy). Cells were injected into the lateral
tail vein of NSG mice (1 x 106 cells per mouse, 5 mice/group). Mice
were inspected daily and sacrificed as soon as they developed diseasesymptoms or after 20 weeks. Mice were then sacrificed and BM cells
recovered. ALL engraftment was measured by flow cytometry. A
detailed description of mouse experiments is provided in the
Supplement.
Statistical Analysis
Statistical evaluations are described in the Supplement.
Results
CD34+/CD38− ALL Stem Cells Express a Unique Profile of
Cell Surface Antigens
As assessed by flow cytometry, CD34+/CD38− ALL LSCs
invariably expressed the stem cell-homing receptors CD44 and
CXCR4 (CD184) (Table 1 and Supplementary Table S5). CD19 was
identified on LSCs in patients with B-lineage ALL, but was not
detected on LSCs in patients with T ALL or CML. Interestingly,
LSCs displayed CALLA (CD10) in patients with Ph+ ALL but not in
patients with Ph− ALL (Table 1). IL-1RAP, a LSC marker in CML,
was found to be expressed on ALL LSCs in a subset of patients (13/
29 = 45%), including most cases (7/11; 64%) with Ph+ ALL
(Supplementary Table S5). CD25 was detected on CD34+/CD38−
ALL LSCs in 12/41 patients (29%), including 11/20 (55%) with Ph+
ALL (Supplementary Table S5). CD26 was expressed on ALL LSCs
in 5/38 patients (13%), including 5/19 (26%) with Ph+ ALL. In Ph−
ALL, CD34+/CD38− LSCs expressed IL-1RAP in a subset of cases
(6/18 = 33%), but displayed CD25 in only 1/21 patients (5%), and
did not exhibit CD26 (0/20) (Table 1; Supplementary Table S5).
Normal CD34+/CD38− BM stem cells did not express CD25, CD26
or IL-1RAP. Since NSG-engrafting LSC also reside in the CD34+/
CD38+ fractions of ALL, we also examined this cell-subset. In
patients with Ph+ ALL, these cells expressed CD10, CD44, CD184
and IL-1RAP (Supplementary Tables S6 and S7). Overall, the
phenotype of CD34+/CD38+ stem/progenitor cells in our ALL
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(Supplementary Tables S6 and S7). Again, CD26 was only expressed
on CD34+/CD38+ cells in a subset of patients with Ph+ ALL. In
patients with Ph-negative ALL, CD34+/CD38+ cells were found to
lack CD25, CD26 and IL-1RAP.
Correlation Between the Molecular Type of ALL and the
Phenotype of LSCs
We have recently shown that CD34+/CD38− LSCs in Ph+ CML
co-express IL-1RAP, CD25 and CD26 [29]. In the current study, weFigure 1. Expression of CD25, CD26, and IL-1RAP on CD34+/CD38− LS
ABL1p210 (upper panel), Ph
+ ALL with BCR/ABL1p190 (middle panel) or Ph
CD45, CD25, CD26 and IL-1RAP. Expression of CD25, CD26 and IL-1R
cytometry. The black open histograms show the isotype control and the
IL-1RAP (right panel) expression on CD34+/CD38− cells. B: qPCR analys
panels) and IL-1RAP mRNA (lower panels) in CD34+/CD38− cells and C
panels), Ph+ALLwithBCR/ABL1p190 (middlepanels) orPh
+ALLwithBCRfound that the phenotype of ALL LSCs correlates with the variant of
BCR/ABL1 (p190 vs p210). In fact, in 5/6 ALL patients with BCR/
ABL1p210, CD34
+/CD38− LSCs expressed CD26 (Figure 1A; Table 1;
Supplementary Table S5). By contrast, in ALL patients with BCR/
ABL1p190 (n = 12), LSCs failed to express CD26 (Figure 1A, Table 1).
However, in most of the BCR/ABL1p190
+ patients, CD34+/CD38−
LSCs stained positive for CD25 and IL-1RAP. Thus, the
LSC-phenotype in BCR/ABL1p210
+ ALL closely resembles that of Ph+
CML except for expression of lymphoid antigens in ALL LSCs
Expression of surface markers on ALL LSCs was confirmed by qPCR.CsA: Bone marrow (BM) cells from patients with Ph+ ALL with BCR/
− ALL (lower panel) were stained with antibodies against CD34, CD38,
AP on CD45+/CD34+/CD38− cells was analyzed by multicolor flow
red histograms represent CD25 (left panel), CD26 (middle panel) and
is of expression of CD25 mRNA (upper panels), CD26 mRNA (middle
D34+/CD38+ cells obtained from each 3 patients with Ph− ALL (left
/ABL1p210 (right panels).mRNA levels are expressedaspercentofABL1.
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BCR/ABL1p210 contained transcripts for CD25 and CD26 (Figure
1B). In ALL patients with BCR/ABL1p190, LSCs expressed low
amounts of CD26 mRNA but no detectable CD25 (Figure 1B). Based
on our engraftment results in NSG mice, we also examined CD34+/
CD38+ cells. As shown in Supplementary Tables S6 and S7, these cells
expressed CD25, CD44, and CD184 in most patients, independent of
the ALL-type. In 5/6 patients with Ph+ ALL exhibiting BCR/
ABL1p210, CD34
+/CD38+ cells co-expressed CD26. By contrast, in
patients with BCR/ABL1p190
+ ALL or Ph− ALL, CD34+/CD38+ cells
did not express CD26 (Supplementary Table S6 and S7).
ALL LSCs Express a Unique Profile of Cytokine Receptors
Growth and function of LSCs are considered to be regulated by
various cytokines and their receptors. As assessed by flow cytometry,
CD34+/CD38− LSCs were found to display IL-2RA (CD25),
IL-3RA (CD123) and IL-1RAP in a majority of patients with Ph+
ALL (Supplementary Table S8A). IL-3RA was also detectable on Ph−
ALL LSCs. An unexpected observation was that in patients with
B-lineage ALL, LSCs lacked CD117 (KIT). By contrast, KIT was
detected on normal CD34+/CD38− stem cells, CML LSCs and LSCs
in patients with T ALL. ALL LSCs expressed only low amounts of
G-CSFR (CD114) and stained negative for the thrombopoietin
(TPO) receptor (CD110) and erythropoietin (EPO) receptor
(Supplementary Table S8A). We also examined the expression of
cytokine receptors on CD34+/CD38+ cells in our ALL patients.
Similar to LSCs, the CD34+/CD38+ stem/progenitor cells expressed
IL-2RA, IL-3RA and IL-1RAP in a majority of the patients
(Supplementary Table S8B).
Effects of Signal Transduction Blockers on Expression of CD25,
CD26 and IL-1RAP
We next investigated whether aberrant expression of CD25, CD26
or IL-1RAP is triggered by BCR/ABL1 or other signaling molecules.
To address this question, we incubated ALL cell lines with BCR/
ABL1-targeting TKIs (imatinib, nilotinib, ponatinib), the PI3 kinase/
mTOR blocker BEZ235, the mTOR blocker RAD001, the MEK
inhibitors RDEA119 and PD0325901, and the STAT5-targeting
drug pimozide. We found that ponatinib, BEZ235 and RAD001
down-regulate expression of IL-1RAP in the IL-1RAP+ cell linesTable 2. Expression of Molecular Targets on ALL LSCs, CML LSCs, and Normal BM Stem Cells
Expression on CD34+/CD38− Cells In
BCR/ABL1p210
Marker Antigen T ALL Ph− ALL
CD20 MS4A1 − −
CD22 Siglec-2 n.t. +/−
CD23 FcεRII − −
CD25 IL-2RA − −
CD30 Ki-1 − −
CD33 Siglec-3 +/− +/−
CD44 HCAM n.t. +
CD52 CAMPATH-1 −/+ −/+
CD117 KIT/SCFR + −/+
CD123 IL-3RA + +
CD135 FLT-3 +/− −/+
CD300a CMRF-35H n.t. +/−
Expression of markers on CD34+/CD38− bone marrow (BM) cells was determined by multi-color flo
Abbreviations: ALL, acute lymphoblastic leukemia; LSCs, leukemic stem cells; CML, chronic myeloid leukemia;
fluorescence intensity (MFI) N 3) in N80% of patients; +/−, LSCs positive in 30–80%; −/+, LSCs positive in 10–
are shown in Supplemental Table S5.RAMOS and REH (Supplementary Figure S2A), whereas the other
inhibitors induced no significant effects. Interestingly, ponatinib,
BEZ235 and RAD001 also upregulated CD25 expression in the
CD25+ cell lines BL-41 and RAMOS (Supplementary Figure S2A).
By contrast, the other compounds tested did not modulate CD25
expression (data not shown). Unexpectedly, the STAT5-targeting
drug pimozide (up to 10 μM) did not inhibit CD25 expression in
ALL cells. Furthermore, we tested the effect of BCR/ABL1 on
expression of CD25, CD26 and IL-1RAP using M-07e cells
expressing or lacking BCR/ABL1. In these experiments, BCR/
ABL1 failed to induce the expression of CD25, CD26 or IL-1RAP
mRNA (Supplementary Figure S2B).
ALL LSCs Express Several Druggable Cell Surface Targets
Several cell surface antigens serve as molecular targets in clinical
hematology. We found that LSCs in B-lineage ALL frequently
co-express CD20, CD22, CD33, and CD52. These targets were
identified on CD34+/CD38- LSCs in patients with Ph+ and Ph- ALL
by flow cytometry and qPCR (Table 2, Figure 2). In addition, we found
that in most patients with ALL, CD34+/CD38+ stem/progenitor cells
express CD22, CD33 and CD52 (Supplementary Table S7B). We also
examined our cell lines for expression of these targets. As shown in
Supplementary Table S9, CD20, CD33 and CD52 were expressed
variably on these cells, namely Z-119 (CD33+), BV-173 (CD33+),
NALM-1 (CD52+), TOM-1 (CD20+), BL-41 (CD20+/CD52+),
RAJI (CD20+/CD52+), RAMOS (CD20+), REH (CD52+) and
CML-T1 (CD52+).
Antibody-Based Targeted Drugs Can Kill ALL LSCs In Vitro
Alemtuzumab induced rapid cell lysis in all CD52+ ALL cell lines
but not in CD52-negative cell lines (Figure 3, A and B). Cell lysis
occurred in complement-containing serum but not in
complement-free (heat-inactivated) serum (Figure 3A). In addition,
alemtuzumab induced cell lysis in primary LSCs in all patients in
whom LSCs expressed CD52, but not in CD52-negative LSCs
(Figure 3C). We also examined the effects of rituximab and GO. Both
agents were found to induce lysis or/and apoptosis in cell lines
expressing the respective target(s), whereas no comparable effects were
seen in CD20-negative and/or CD33-negative cells (Supplementary
Figure S3). Corresponding results were obtained with primaryBCR/ABL1p190
Ph+ ALL Ph+ ALL CML Normal BM
+/− −/+ − −
+ + n.t. −
− − − −
+ +/− + −
−/+ +/− + −
+/− −/+ + +
+ + + +
+/− +/− −/+ +/−
− − + +
+ + + +
−/+ − +/− −/+
+ + + +
w cytometry as described.30,35,36 Technical details are provided in the Supplemental Material.
BM, bone marrow; CD, cluster of differentiation; n.t., not tested. Score of reactivity: +, LSCs positive (median
29%; −, LSCs positive in b10% of patients. Antibody staining results obtained in each individual ALL patient,
Figure 2. Expression of CD20, CD33, and CD52 on ALL LSCsA: Bone marrow (BM) cells from patients with Ph+ ALL with BCR/ABL1p210
(upper panels), Ph+ ALL with BCR/ABL1p190 (middle panels) or Ph
− ALL (lower panels) were stained with antibodies against CD34, CD38,
CD45, CD20, CD33 and CD52. Expression of CD20, CD33 and CD52 on CD45+/CD34+/CD38− cells was analyzed by multicolor flow
cytometry. The black open histograms show the isotype control and the red histograms represent CD20 (left panel), CD33 (middle panel) and
CD52 (right panel) expression on CD34+/CD38− cells. B: qPCR analysis of expression of CD20 mRNA (upper panels), CD33 mRNA (middle
panels) andCD52mRNA (lower panels) inCD34+/CD38− cells andCD34+/CD38+ cells obtained fromeach3patientswithPh−ALL (left panels),
Ph+ ALL with BCR/ABL1p190 (middle panels) or Ph
+ ALL with BCR/ABL1p210 (right panels). mRNA levels are expressed as percent of ABL1.
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itor cells (Supplementary Figures S4 and S5). As expected, BCR/
ABL1 TKIs suppressed the proliferation of BCR/ABL1+ ALL cell
lines and of CML-T1 cells, but did not inhibit growth of Ph-negative
cells. In most cell lines, GO also blocked cell proliferation
(Supplementary Table S10). Finally, we examined cooperative
anti-neoplastic effects in the CD33+/Ph+ cell line Z-119. We
found that the drug combinations GO+imatinib, GO+nilotinib and
GO+ponatinib produce synergistic growth-inhibitory effects on
Z-119 cells (Supplementary Figure S6).Effects of Targeted Antibodies on Engraftment of Ph+ ALL
Cells in NSG Mice
In order to confirm that NSG-repopulating Ph+ ALL LSCs indeed
reside in a CD34+/CD38− cell fraction, we isolated these cells and
injected them into NSG mice. As shown in Figure 4A, control MNCs
as well as sorted CD34+/CD38− ALL cells produced leukemic
engraftment with comparable engraftment levels in NSG mice after
16–20 weeks. However, surprisingly, CD34+/CD38+ ALL cells were
also found to produce leukemic engraftment in NSGmice (Figure 4A).
Moreover, xenograft-derived ALL cells obtained from all three primary
638 Characterization of ALL Stem Cells Blatt et al. Neoplasia Vol. 20, No. xx, 2018sample-sources (MNCs, CD34+/CD38− and CD34+/CD38+ cells)
engrafted secondary and tertiary recipient mice (Supplementary Table
S11). Based on these results, total MNCs (containing both, CD34+/
CD38− and CD34+/CD38+ cells) were used in drug incubation
experiments. In particular, we pre-incubated primary ALLMNCs with
GO (10 μg/mL), alemtuzumab (500μg/mL), or a combination of both
drugs for 1 hour before injecting these cells into NSG mice.
Pre-incubation with the drug-combination resulted in reduced
engraftment of ALL cells, whereas no substantial effects of single
drug-exposures were seen (Fig. 4B). Finally, we injected the CD52+ line
BL-41 into NSGmice and treated these mice either with control-buffer
or alemtuzumab (250 μg) for 5 weeks. In these experiments,
alemtuzumab was found to interfere with leukemic engraftment of
BL-41 cells (Fig. 4C) and to counteract leukemia-induced weight loss in
NSG mice (Supplementary Fig. S7).
Prognostic Impact of LSC Markers in Patients With ALL
To define the prognostic significance of expression of various
surface markers on ALL LSCs, we correlated overall survival (OS)
with expression of CD20, CD25, CD33, and CD52 on LSCs. These
markers were differentially expressed on LSCs in patient-subgroups.
Accordingly, patients were split into high and low ´LSC-expressers´.
We found that higher levels of CD25 and CD33 on LSCs were
associated with an increased OS in our ALL patients (Fig. 5).
However, the differences did not reach statistical significance. The
other markers examined did not correlate with OS.
Discussion
During the past few years, substantial efforts have been made to
identify markers and targets expressed on LSCs in various human
leukemias [22,23,26–34]. However, so far, only little is known about
the phenotype and function of LSCs in ALL. In patients with Ph+
ALL, the NOD/SCID-repopulating LSCs may reside preferentially in
a CD34+/CD38− cell fraction [30–32]. In the current study, we
established the phenotype of CD34+/CD38− LSCs in adult patients
with Ph+ ALL and Ph− ALL. We found that CD34+/CD38− LSCs in
Ph+ ALL exhibiting BCR/ABL1p210 co-express CD25, CD26 and
IL-1RAP in an aberrant manner, thereby resembling the phenotype
of CML LSCs [29,38]. Whereas CD25 and IL-1RAP were alsoFigure 3. Effects of alemtuzumab on growth and survival of
neoplastic cellsA: NALM-1 cells (CD52+), BL-41 cells (CD52+),
RAJI cells (CD52+) and REH cells (CD52+) and B: BV-173 cells
(CD52−) TOM-1 cells (CD52−), Z-119 cells (CD52−) and RAMOS
cells (CD52−) were incubated in various concentration of alemtu-
zumab (10–300 μg/mL) in RPMI-1640 medium with either 30%
serum (black bars), or 30% heat-inactivated serum (open bars) at 37
°C for 1 hour. Thereafter, cells were stained with propidium iodide
(PI) and analyzed for cell viability on a FACSCalibur. Results
represent the mean ± SD from 3 independent experiments.
Asterisk (*): P b .05. C: Primary cells from patients with ALL with
CD52+ LSCs (#18, #19 and #20; upper panel) or patients with ALL
with CD52− LSCs (#44, #46 and #48; lower panel) were incubated
in alemtuzumab (10–300 μg/mL) in the presence of 30% human
serum at 37 °C (5% CO2) for 1 hour. Then 10 μL calibration beads
were added. Cells were washed and then stained with antibodies
against CD34, CD45, and CD38 for 15 minutes. Cells were then
subjected to DAPI staining to count viable cells on a FACSCanto II.
The left panels (black bars) show the effects of alemtuzumab on
CD34+/CD38− cells and the right panels (open bars) show the
effects of alemtuzumab onCD34+/CD38+ cells. Results represent the
mean ± SD from 3 independent experiments. Asterisk (*): P b .05.
Figure 4. Engraftment of ALL cells in NSG miceA: Three different
fractions of ALL cells were injected intravenously into female NSG
mice (5/group): total MNCs depleted of CD3+ T cells (control
MNCs), CD34+/CD38− cells and CD34+/CD38+ cells. B: T
cell-depleted MNCs were pre-incubated in control medium,
alemtuzumab (500 μg/mL), GO (10 μg/mL), or a combination of
alemtuzumab (500 μg/mL) and GO (10 μg/mL) at 37 °C for 1 hour
prior to injection. A,B: After a maximum observation period of
12–20 weeks, mice were sacrificed and bone marrow (BM) cells
(humeri, tibias, femurs) recovered for flow cytometry. Multi-color
flow cytometry was performed using antibodies against CD19,
CD33, and CD45. TO-PRO-3 was used to exclude non-viable cells.
Engraftment was defined as at least 1% human CD45+ cells in
mouse BM samples. Asterisk (*): P b .05. C: NSG mice were
intravenously injected with BL-41 cells (1 x 105/mouse). At day 7,
mice were split into two groups and treated with either
alemtuzumab (250 μg intraperitoneally three times a week; 9
mice) or PBS (vehicle control; 5 mice). After 5 weeks, mice were
sacrificed. Multicolor flow cytometry was performed on BM cells
using antibodies against CD20, CD45 and CD52 to determine
engraftment levels.
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exhibiting BCR/ABL1p190, CD26 was found to be expressed
exclusively on ALL LSCs in patients with BCR/ABL1p210, but notin patients with BCR/ABL1p190
+ ALL or Ph− ALL. The preferential
expression of CD25 on immature progenitor cells in Ph+ ALL
compared to Ph− ALL confirms previous studies [39]. We also found
that both CD34+/CD38− and CD34+/CD38+ ALL cells engraft
NSG mice and that both populations frequently express druggable
cell surface targets, including CD20, CD33, and CD52 which may
be relevant clinically and may provide a basis for the design of novel
LSC-eradicating and thus potentially curative treatment concepts.
During early lymphopoiesis, B cell precursors co-express CD34
and CD19, whereas later, during maturation, these cells lose CD34
and acquire additional lymphoid markers, including CD19 and
CD20 [40,41]. In our patients with B-lineage ALL, CD34+/CD38−
LSCs co-expressed CD19 in all samples tested, thereby confirming
the lymphoid nature of these cells. Moreover, in a considerable
number of patients, ALL LSCs co-expressed CD10, CD20, and
CD22. In addition, we were able to show that purified (sorted) LSCs
in Ph+ ALL display BCR/ABL1 mRNA, confirming their clonal
origin. In patients with T ALL and CML, LSCs did not express
CD19 or CD20. An interesting observation was that LSCs display
CALLA (CD10) in patients with Ph+ ALL but not in Ph− ALL.
We and others have recently shown that LSCs in CML express
CD25, CD26, and IL-1RAP in an aberrant manner [29,38,42].
Therefore, we were interested to learn whether LSCs in our ALL
patients express one or more of these LSC-antigens. The results of
our study show that LSCs in Ph+ ALL often express CD25 and
IL-1RAP, whereas LSCs in most patients with Ph− ALL did not
express CD25, and IL-1RAP was only detected on LSCs in a subset
of these patients. In a distinct group of patients with Ph+ ALL,
namely those where the lymphoblasts exhibited BCR/ABL1p210,
LSCs and CD34+/CD38+ stem/progenitor cells also expressed
CD26. These data suggest that the phenotype of stem cells in Ph+
ALL exhibiting BCR/ABL1p210 is almost identical to that of CML
LSCs [29]. This observation supports the close relationship between
these two leukemias. It is noteworthy in this regard, that Ph+ ALL
expressing BCR/ABL1p210 is often regarded as primary lymphoid
blast phase of CML.
Currently, it remains unknown why stem and progenitor cells in
BCR/ABL1p190
+ ALL usually lack IL-1RAP and CD26. A possible
explanation for this difference is that the two forms of BCR/ABL1
activate different signaling networks [43,44]. Therefore, we believe
that these different signaling pathways and the related oncogenic
machineries might be responsible for differential expression of CD26
and other surface molecules on ALL LSCs. For example, it has been
described that in Ph+ CML, the STAT5 pathway contributes to
aberrant expression of CD25 on LSC [45].
In the current study, we first asked whether BCR/ABL1 could be
responsible for aberrant expression of these antigens. However, no
effects of imatinib or nilotinib on expression of CD25, CD26 or
IL-1RAP in ALL cells were seen. In addition, introduction of BCR/
ABL1 into the Ph-negative cell line M-07e did not induce CD25,
CD26 or IL-1RAP mRNA expression suggesting that other pathways
and molecules are involved. Next, we applied the multi-kinase blocker
ponatinib, the PI3 kinase/mTOR inhibitor BEZ235, and RAD001.
These drugs were found to down-regulate IL-1RAP expression in the
IL-1RAP+ cell lines RAMOS and REH, suggesting that the PI3
kinase/mTOR pathway contributes to expression of IL-1RAP.
However, these drugs did not downregulate expression of CD25 in
the ALL cell lines tested. Rather, BEZ235 and RAD001 even
upregulated expression of CD25 on REH and RAMOS cells. This is
Figure 5. Influence of expression of CD20, CD25, CD33 and CD52 on LSCs on survival in ALL patientsThe probability of overall survival
(OS) in patients with ALL (n = 49) was determined for subgroups of patients in whom CD34+/CD38− stem cells either expressed (pos) or
did not express (neg) substantial levels of CD20, CD25, CD33 or CD52. Expressers (pos) were defined as a median fluorescence intensity
(MFI) of ≥3 and low expressers (neg) as a MFI of b3. The median follow-up of our ALL patients was 623 days. The probability of OS was
calculated by the product limit method of Kaplan and Meier.
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described in CML LSCs [45].
We also examined the potential prognostic role of aberrantly
expressed surface antigens on ALL LSCs. While most LSC markers
did not define a distinct prognostic subgroup, expression of CD25
and CD33 on ALL LSCs was found to be associated with improved
OS which was an unexpected result. In fact, in patients with AML
expression of CD25 and CD52 has been associated with a poor
survival [37,46]. On the other hand, CD25 has been described as a
growth-suppressor in CML cells [45]. Whether CD25 can act as a
growth-suppressing molecule in ALL LSCs remains unknown.
ALL LSCs were also found to express receptors for various
cytokine-ligands, including IL-2RA (CD25), IL-3RA (CD123) and
CD135 (FLT3). Interestingly, ALL LSCs in T ALL also expressed
KIT (CD117) whereas in B-lineage ALL, CD34+/CD38− LSCs were
found to lack KIT, suggesting that KIT does not serve as a major
regulator of LSC-function in B-lineage ALL. Correspondingly, the
KIT-targeting TKIs imatinib or nilotinib did not show
growth-inhibitory effects on Ph-negative ALL cells. The EPO and
TPO receptors were not detected on LSCs in Ph+ and Ph− ALL. The
G-CSF receptor (CD114) was found to be expressed on ALL LSCs
either at low level or was not detected on LSCs. These data may have
clinical implications as some of these cytokines are applied in clinical
practice during and/or after chemotherapy.
We also identified several druggable surface antigens on ALL LSCs.
Among these were CD20, CD33, and CD52. We therefore asked
whether antibody-based drugs directed against these molecules would
induce cell death in LSCs. The results of our study show that these
targeted antibodies are indeed able to induce cell death in ALL LSCs
in vitro. However, responses were only seen in patients in whom LSCs
expressed these targets, but not in those in whom LSCs did notexpress these target-antigens. Finally, we tested the hypothesis that
these drugs can interfere with leukemic engraftment of LSCs in NSG
mice. Since our data showed that both, CD34+/CD38− and CD34+/
CD38+ ALL cells produce engraftment, we used T cell-depleted
MNCs (bulk of CD34+ cells) in these experiments. However, neither
GO alone nor alemtuzumab alone were able to inhibit ALL
engraftment in NSG mice, suggesting that some of the LSCs in
these cell-fractions were resistant or did not express these targets. On
the other hand, a combination of both drugs was found to
substantially inhibit engraftment of ALL cells in NSG mice. These
data suggest that CD33 and CD52 are variably expressed in
sub-fractions of ALL LSCs, and that combined targeting is required
to block LSC engraftment. An alternative explanation would be that
ALL LSCs can recover rapidly from drug effects in vivo in mice unless
multiple drugs are applied. We therefore transplanted the CD52+
ALL cell line BL-41 into NSG mice and asked whether continuous
treatment with alemtuzumab is able to interfere with ALL expansion.
Indeed, alemtuzumab i.p. injection three times a week led to a
significant decrease in engraftment. However, again, no total
depletion of ALL cells was achieved. Together, these data suggest
that targeting through defined surface antigens may be a promising
approach to attack LSCs, but these drugs have to be combined with
each other or with other drugs to achieve optimal anti-neoplastic
effects.
The application of targeted antibodies in lymphoid malignancies
has led to an improvement of the overall outcome and long-term
disease-free survival. An impressive example is the use of
CD20-targeting antibodies as adjunct to chemotherapy in patients
with CD20+ Non Hodgkin lymphomas [47–49]. In ALL, the
application of targeted antibodies has recently also been proposed
[50,51]. In the present study, we show that such ´antibody+TKI´
Neoplasia Vol. 20, No. xx, 2018 Blatt et al. 641combinations can produce additive or even synergistic effects on
growth and survival of Ph+ ALL cell lines.
In conclusion, our data show that ALL LSCs display a distinct
phenotype, including aberrantly expressed markers and druggable
target-antigens. Aberrantly expressed surface antigens, such as CD25,
IL-1RAP or CD26 may serve as diagnostic LSC markers and may
assist in enrichment of LSCs and their separation from normal stem
cells. The druggable targets identified may provide a basis for the
design of novel LSC-eliminating treatment-strategies, including
antibody-based therapies and novel CAR-T cell-based
immunotherapies.
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